LIVIVO - Search results -

Search results

Result 1 - 10 of total 24150

Search options

Article: A Mechanism Exploration for the Yi-Fei-San-Jie Formula against Non-Small-Cell Lung Cancer Based on UPLC-MS/MS, Network Pharmacology, and

Hu, Leihao / He, Canfeng / Mo, Aier / Zhan, Xingkai / Yang, Caizhi / Guo, Wei / Sun, Lingling / Su, Weiwei / Lin, Lizhu

Evidence-based complementary and alternative medicine : eCAM

2023 Volume 2023, Page(s) 3436814

Abstract: Non-small-cell lung cancer (NSCLC) is one of the most prevalent cancers worldwide. A Yi-Fei-San-Jie ...

Abstract	Non-small-cell lung cancer (NSCLC) is one of the most prevalent cancers worldwide. A Yi-Fei-San-Jie formula (YFSJF), widely used in NSCLC treatment in south China, has been validated in clinical studies. However, the pharmacological mechanism behind it remains unclear. In this study, 73 compounds were identified using ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), with 58 enrolled in network pharmacology. The protein-protein interaction network, functional enrichment analysis, and compound-target-pathway network were constructed using 74 overlapping targets from 58 drugs and NSCLC. YFSJF has many targets and pathways in the fight against NSCLC. PIK3R1, PIK3CA, and AKT1 were identified as key targets, and the PI3K/AKT pathway was identified as the key pathway. According to the Human Protein Atlas (THPA) database and the Kaplan-Meier Online website, the three key targets had varying expression levels in normal and abnormal tissues and were linked to prognosis. Molecular docking and dynamics simulations verified that hub compounds have a strong affinity with three critical targets. This study revealed multiple compounds, targets, and pathways for YFSJF against NSCLC and suggested that YFSJF might inhibit PIK3R1, PIK3CA, and AKT1 to suppress the PI3K/AKT pathway and play its pharmacological role.
Language	English
Publishing date	2023-01-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	2171158-6
ISSN	1741-4288 ; 1741-427X
ISSN (online)	1741-4288
ISSN	1741-427X
DOI	10.1155/2023/3436814
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5995: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Modified Bu-Fei decoction inhibits lung metastasis via suppressing angiopoietin-like 4.

Hao, Huifeng / Guo, Zhengwang / Li, Zhandong / Li, Junfeng / Jiang, Shantong / Fu, Jialei / Jiao, Yanna / Deng, Xinxin / Han, Shuyan / Li, Pingping

Phytomedicine : international journal of phytotherapy and phytopharmacology

2022 Volume 106, Page(s) 154409

Abstract: Background: Modified Bu-Fei decoction (MBFD), a formula of traditional Chinese medicine, is used ...

Abstract	Background: Modified Bu-Fei decoction (MBFD), a formula of traditional Chinese medicine, is used for treating lung cancer in clinic. The actions and mechanisms of MBFD on modulating lung microenvironment is not clear. Purpose: Lung microenvironment is rich in vascular endothelial cells (ECs). This study is aimed to examine the actions of MBFD on tumor biology, and to uncover the underlying mechanisms by focusing on pulmonary ECs. Methods: The Lewis lung carcinoma (LLC) xenograft model and the metastatic cancer model were used to determine the efficacy of MBFD on inhibiting tumor growth and metastasis. Flow cytometry and trans-well analysis were used to determine the role of ECs in anti-metastatic actions of MBFD. The in silico analysis and function assays were used to identify the mechanisms of MBFD in retarding lung metastasis. Plasma from lung cancer patients were used to verify the effects of MBFD on angiogenin-like protein 4 (ANGPTL4) in clinical conditions. Results: MBFD significantly suppressed spontaneous lung metastasis of LLC tumors, but not tumor growth, at clinically relevant concentrations. The anti-metastatic effects of MBFD were verified in metastatic cancer models created by intravenous injection of LLC or 4T1 cells. MBFD inhibited lung infiltration of circulating tumor cells, without reducing tumor cell proliferations in lung. In vitro, MBFD dose-dependently inhibited trans-endothelial migrations of tumor cells. RNA-seq assay and verification experiments confirmed that MBFD potently depressed endothelial ANGPTL4 which is able to broke endothelial barrier and protect tumor cells from anoikis. Database analysis revealed that high ANGPTL4 levels is negatively correlated with overall survival of cancer patients. Importantly, MBFD therapy reduced plasma levels of ANGPTL4 in lung cancer patients. Finally, MBFD was revealed to inhibit ANGPTL4 expressions in a hypoxia inducible factor-1α (HIF-1α)-dependent manner, based on results from specific signaling inhibitors and network pharmacology analysis. Conclusion: MBFD, at clinically relevant concentrations, inhibits cancer lung metastasis via suppressing endothelial ANGPTL4. These results revealed novel effects and mechanisms of MBFD in treating cancer, and have a significant clinical implication of MBFD therapy in combating metastasis.
MeSH term(s)	Angiopoietins/metabolism ; Angiopoietins/therapeutic use ; Animals ; Carcinoma, Lewis Lung/drug therapy ; Carcinoma, Lewis Lung/pathology ; Cell Line, Tumor ; Drugs, Chinese Herbal/therapeutic use ; Endothelial Cells ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Lung Neoplasms/pathology ; Tumor Microenvironment
Chemical Substances	Angiopoietins ; Drugs, Chinese Herbal ; Hypoxia-Inducible Factor 1, alpha Subunit ; bu-fei decoction
Language	English
Publishing date	2022-08-28
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1205240-1
ISSN	1618-095X ; 0944-7113
ISSN (online)	1618-095X
ISSN	0944-7113
DOI	10.1016/j.phymed.2022.154409
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4115: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Fe

Zhang, Wei / Wu, Wei / Guo, Fei / Dong, Xinwei

Journal of colloid and interface science

2023 Volume 640, Page(s) 1068–1079

Abstract: ... Herein, we designed and successfully fabricated a series of Fe-doped ZIF-x with different morphologies ... After high-temperature calcination, Fe ...

Abstract	The control of morphology, structure and composition of metal-organic frameworks derived metal-nitrogen doped porous carbon (M-N-C) with high precision and accuracy is essential for the catalytic performance. While single-atom or small-sized nanometer catalysts show notable effects in catalysis, one catalyst combining the advantages of single-atom and nanometer catalysts may cultivate more benefits. Herein, we designed and successfully fabricated a series of Fe-doped ZIF-x with different morphologies (cube→truncated hexahedron→truncated octahedron) in one pot by simply adjusting the adding amount of vitamin C. After high-temperature calcination, Fe
Language	English
Publishing date	2023-03-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	241597-5
ISSN	1095-7103 ; 0021-9797
ISSN (online)	1095-7103
ISSN	0021-9797
DOI	10.1016/j.jcis.2023.03.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Bonn / Germany

Z 71/707: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reduction in gefitinib resistance mediated by Yi-Fei San-Jie pill in non-small cell lung cancer through regulation of tyrosine metabolism, cell cycle, and the MET/EGFR signaling pathway.

Yang, Cai-Zhi / Guo, Wei / Wang, Yi-Fan / Hu, Lei-Hao / Wang, Jing / Luo, Jia-Min / Yao, Xiao-Hui / Liu, Shan / Tao, Lan-Ting / Sun, Ling-Ling / Lin, Li-Zhu

Journal of ethnopharmacology

2023 Volume 314, Page(s) 116566

Abstract: Ethnopharmacological relevance: The Chinese herbal prescription Yi-Fei San-Jie pill (YFSJ) has ...

Abstract	Ethnopharmacological relevance: The Chinese herbal prescription Yi-Fei San-Jie pill (YFSJ) has been used for adjuvant treatment in patients with lung cancer for a long time. Aim of the study: Reports have indicated that the combination of gefitinib (Gef) with YFSJ inhibits the proliferation of EGFR-TKI-resistant cell lines by enhancing cellular apoptosis and autophagy in non-small cell lung cancer (NSCLC). However, the molecular mechanisms underlying the effect of YFSJ on EGFR-TKI resistance and related metabolic pathways remain to be explored. Materials and methods: In our report, ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), metabolomics, network pharmacology, bioinformatics, and biological analysis methods were used to investigate the mechanism. Results: The UPLC-MS/MS data identified 42 active compounds of YFSJ extracts. YFSJ extracts can enhance the antitumor efficacy of Gef without hepatic and renal toxicity in vivo. The analysis of the metabolomics pathway enrichment revealed that YFSJ mainly affected the tyrosine metabolism pathway in rat models. Moreover, YFSJ has been shown to reverse Gef resistance and improve the effects of Gef on the cellular viability, migration capacity, and cell cycle arrest of NSCLC cell lines with EGFR mutations. The results of network pharmacology and molecular docking analyses revealed that tyrosine metabolism-related active compounds of YFSJ affect EGFR-TKIs resistance in NSCLC by targeting cell cycle and the MET/EGFR signaling pathway; these findings were validated by western blotting and immunohistochemistry. Conclusions: YFSJ inhibits NSCLC by inducing cell cycle arrest in the G1/S phase to suppress tumor growth, cell viability, and cell migration through synergistic effects with Gef via the tyrosine metabolic pathway and the EGFR/MET signaling pathway. To summarize, the findings of the current study indicate that YFSJ is a prospective complementary treatment for Gef-resistant NSCLC.
MeSH term(s)	Rats ; Animals ; Carcinoma, Non-Small-Cell Lung/pathology ; Gefitinib/pharmacology ; Gefitinib/therapeutic use ; Lung Neoplasms/pathology ; Molecular Docking Simulation ; Chromatography, Liquid ; Prospective Studies ; ErbB Receptors/metabolism ; Drug Resistance, Neoplasm ; Tandem Mass Spectrometry ; Signal Transduction ; Cell Cycle ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Cell Proliferation
Chemical Substances	Gefitinib (S65743JHBS) ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors
Language	English
Publishing date	2023-05-09
Publishing country	Ireland
Document type	Journal Article
ZDB-ID	134511-4
ISSN	1872-7573 ; 0378-8741
ISSN (online)	1872-7573
ISSN	0378-8741
DOI	10.1016/j.jep.2023.116566
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1494: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The advertisement call of Leptobrachella liui Fei and Ye, 1990 (Anura: Megophryidae).

Ding, Guo-Hua / Chen, Zhi-Qiang / Tang, Yun / Lin, Zhi-Hua

Zootaxa

2019 Volume 4576, Issue 3, Page(s) zootaxa.4576.3.11

Abstract: ... from southern China: L. alpina (Fei, Ye Li, 1990), L. laui (Sung, Yang Wang, 2014), L. liui (Fei Ye, 1990), L ... yunkaiensis (Wang, Li, Lyu Wang, 2018), L. ventripunctata (Fei, Ye Li, 1990), L. pelodytoides (Boulenger, 1893 ...

Abstract	Leptobrachella (Anura: Megophryidae) is currently composed of seventy-one species distributed in China and Southeast Asia (Frost 2018). Fourteen species of Leptobrachella are currently known from southern China: L. alpina (Fei, Ye Li, 1990), L. laui (Sung, Yang Wang, 2014), L. liui (Fei Ye, 1990), L. mangshanensis (Hou, Zhang, Hu, Li, Shi, Chen, Mo Wang, 2018), L. maoershanensis (Yuan, Sun, Chen, Rowley Che, 2017), L. oshanensis (Liu, 1950), L. purpura (Yang, Zeng Wang, 2018), L. tengchongensis (Yang, Wang, Chen Rao, 2016), L. wuhuangmontis (Wang, Yang Wang, 2018), L. yingjiangensis (Yang, Zeng Wang, 2018), L. yunkaiensis (Wang, Li, Lyu Wang, 2018), L. ventripunctata (Fei, Ye Li, 1990), L. pelodytoides (Boulenger, 1893) and L. sungi (Lathrop, Murphy, Orlov Ho, 1998) and the first eleven species are endemic of this region (AmphibiaChina 2018). Many new species in this genus were discovered based on molecular, morphometric and bioacoustic data in recent years (Frost 2018). In comparison to molecular and morphological data, bioacoustics is especially useful in species identification of Leptobrachella in field surveys (Rowley et al. 2016). Although the advertisement calls of many Leptobrachella species were described along with the species descriptions (e.g., Rowley et al. 2016), the advertisement calls of only three Chinese endemic species (L. alpinus; L. laui and L. oshanensis) are known (Jiang et al. 2002; Matsui 2006; Xu et al. 2005). Here, we describe the advertisement calls of L. liui, which inhabits rocky streams in southeastern China (Fujian, Jiangxi and Zhejinag) and is morphologically diagnosed by the combination of a set of external color traits (Fig. 1).
MeSH term(s)	Animals ; Anura ; China ; Color ; Gastropoda ; Phenotype
Language	English
Publishing date	2019-04-03
Publishing country	New Zealand
Document type	Journal Article
ISSN	1175-5334
ISSN (online)	1175-5334
DOI	10.11646/zootaxa.4576.3.11
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Modified Bu-Fei decoction inhibits lung metastasis via suppressing angiopoietin-like 4

Hao, Huifeng / Guo, Zhengwang / Li, Zhandong / Li, Junfeng / Jiang, Shantong / Fu, Jialei / Jiao, Yanna / Deng, Xinxin / Han, Shuyan / Li, Pingping

Phytomedicine. 2022 Aug. 17,

2022

Abstract: Modified Bu-Fei decoction (MBFD), a formula of traditional Chinese medicine, is used for treating ...

Abstract	: Modified Bu-Fei decoction (MBFD), a formula of traditional Chinese medicine, is used for treating lung cancer in clinic. The actions and mechanisms of MBFD on modulating lung microenvironment is not clear. : Lung microenvironment is rich in vascular endothelial cells (ECs). This study is aimed to examine the actions of MBFD on tumor biology, and to uncover the underlying mechanisms by focusing on pulmonary ECs. : The Lewis lung carcinoma (LLC) xenograft model and the metastatic cancer model were used to determine the efficacy of MBFD on inhibiting tumor growth and metastasis. Flow cytometry and trans-well analysis were used to determine the role of ECs in anti-metastatic actions of MBFD. The in silico analysis and function assays were used to identify the mechanisms of MBFD in retarding lung metastasis. Plasma from lung cancer patients were used to verify the effects of MBFD on angiogenin-like protein 4 (ANGPTL4) in clinical conditions. : MBFD significantly suppressed spontaneous lung metastasis of LLC tumors, but not tumor growth, at clinically relevant concentrations. The anti-metastatic effects of MBFD were verified in metastatic cancer models created by intravenous injection of LLC or 4T1 cells. MBFD inhibited lung infiltration of circulating tumor cells, without reducing tumor cell proliferations in lung. In vitro, MBFD dose-dependently inhibited trans-endothelial migrations of tumor cells. RNA-seq assay and verification experiments confirmed that MBFD potently depressed endothelial ANGPTL4 which is able to broke endothelial barrier and protect tumor cells from anoikis. Database analysis revealed that high ANGPTL4 levels is negatively correlated with overall survival of cancer patients. Importantly, MBFD therapy reduced plasma levels of ANGPTL4 in lung cancer patients. Finally, MBFD was revealed to inhibit ANGPTL4 expressions in a hypoxia inducible factor-1α (HIF-1α)-dependent manner, based on results from specific signaling inhibitors and network pharmacology analysis. : MBFD, at clinically relevant concentrations, inhibits cancer lung metastasis via suppressing endothelial ANGPTL4. These results revealed novel effects and mechanisms of MBFD in treating cancer, and have a significant clinical implication of MBFD therapy in combating metastasis.
Keywords	Oriental traditional medicine ; computer simulation ; databases ; flow cytometry ; hypoxia ; intravenous injection ; lung neoplasms ; lungs ; metastasis ; models ; neoplasm cells ; pharmacology ; sequence analysis ; xenotransplantation
Language	English
Dates of publication	2022-0817
Publishing place	Elsevier GmbH
Document type	Article
Note	Pre-press version
ZDB-ID	1205240-1
ISSN	1618-095X ; 0944-7113
ISSN (online)	1618-095X
ISSN	0944-7113
DOI	10.1016/j.phymed.2022.154409
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 4115: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Deciphering the Effects and Mechanisms of Yi-Fei-San-Jie-pill on Non-Small Cell Lung Cancer With Integrating Network Target Analysis and Experimental Validation.

Yang, Hongxing / Guo, Qiuyan / Wu, Jianbin / Zhong, Lixia / Sun, Lingling / Liu, Wei / Wang, Jigang / Lin, Lizhu

Frontiers in pharmacology

2022 Volume 13, Page(s) 851554

Abstract: ... therapy. Yi-Fei-San-Jie-pill (YFSJ), a well-applicated traditional Chinese medicine formula, was reported ...

Abstract	Non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases, calls for better therapy. Yi-Fei-San-Jie-pill (YFSJ), a well-applicated traditional Chinese medicine formula, was reported to be effective in the treatment of NSCLC. However, its anti-tumor mechanism still needs to be fully elucidated. Herein, a reliable preclinical orthotopic but not subcutaneous model of NSCLC in mice was established to evaluate the anti-cancer properties and further validate the mechanisms of YFSJ. A bioinformatic analysis was executed to identify the potential targets and key pathways of YFSJ on NSCLC. In detail, the anti-tumor effect of YFSJ and the autophagy inhibitor 3-MA was evaluated according to the tumor fluorescence value and comparison of different groups' survival times. As a result, YFSJ markedly decreased tumor size and prolonged survival time in contrast with those in the orthotopic model group (
Language	English
Publishing date	2022-05-11
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2022.851554
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Fe

Wang, Jie / Huang, Qingwen / Guo, Wenbo / Guo, Dakai / Han, Zheng / Nie, Dongxia

Toxins

2023 Volume 15, Issue 2

Abstract: ... nanomaterial Fe ...

Abstract	In this study, a simple and efficient magnetic solid-phase extraction (MSPE) strategy was developed to simultaneously purify and enrich nine mycotoxins in fruits, with the magnetic covalent organic framework nanomaterial Fe
MeSH term(s)	Tandem Mass Spectrometry ; Fruit ; Chromatography, High Pressure Liquid ; Mycotoxins ; Adsorption ; Nanocomposites ; Magnetic Phenomena ; Solid Phase Extraction/methods ; Limit of Detection
Chemical Substances	Mycotoxins ; tyrosine-4-azophenyltrimethylammonium chloride (38299-26-2)
Language	English
Publishing date	2023-02-01
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2518395-3
ISSN	2072-6651 ; 2072-6651
ISSN (online)	2072-6651
ISSN	2072-6651
DOI	10.3390/toxins15020117
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Fe

Zhang, Hao / Wang, Youkui / Zhao, Ruili / Kou, Meimei / Guo, Mengyao / Xu, Ke / Tian, Gang / Wei, Xinting / Jiang, Song / Yuan, Qing / Zhao, Jinsheng

Materials (Basel, Switzerland)

2023 Volume 16, Issue 19

Abstract: In this work, we prepared a green, cheap material by chelating humic acid with ferric ions (HA-Fe ... of the chelation between the ferric ions and HA, the capacity of HA-Fe is 586 mAh·g ...

Abstract	In this work, we prepared a green, cheap material by chelating humic acid with ferric ions (HA-Fe) and used it as an anode material in LIBs for the first time. From the SEM, TEM, XPS, XRD, and nitrogen adsorption-desorption experimental results, it was found that the ferric ion can chelate with humic acid successfully under mild conditions and can increase the surface area of materials. Taking advantage of the chelation between the ferric ions and HA, the capacity of HA-Fe is 586 mAh·g
Language	English
Publishing date	2023-09-29
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2487261-1
ISSN	1996-1944
ISSN	1996-1944
DOI	10.3390/ma16196477
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Chinese patent medicine Fei-Liu-Ping ointment as an adjunctive treatment for non-small cell lung cancer: protocol for a systematic review.

Zheng, Honggang / He, Shulin / Liu, Rui / Xu, Xinyao / Xu, Tao / Chen, Shuntai / Guo, Qiujun / Gao, Yebo / Hua, Baojin

BMJ open

2017 Volume 7, Issue 1, Page(s) e015045

Abstract: Introduction: Fei-Liu-Ping ointment has been widely applied as adjunctive drug in the treatment ... the efficacy of this treatment. Here, we provide a protocol for assessing the effectiveness and safety of Fei-Liu-Ping ointment ... software.: Dissemination: The results of this review will offer implications for the use of Fei-Liu-Ping ...

Abstract	Introduction: Fei-Liu-Ping ointment has been widely applied as adjunctive drug in the treatment of non-small cell lung cancer (NSCLC). However, there has been no systematic review of research findings regarding the efficacy of this treatment. Here, we provide a protocol for assessing the effectiveness and safety of Fei-Liu-Ping ointment in the treatment of NSCLC. Methods and analysis: The electronic databases to be searched will include MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Excerpt Medica Database (EMBASE), China National Knowledge Infrastructure (CNKI), China Scientific Journal Database (VIP), Wanfang Database and Chinese Biomedical Literature Database (CBM). Papers in English or Chinese published from inception to 2016 will be included without any restrictions. We will conduct a meta-analysis of randomised controlled trial if possible. The therapeutic effects according to the standard for treatment of solid tumours by the WHO and the quality of life as evaluated by Karnofsky score and weight will be applied as the primary outcomes. We will also evaluate the data synthesis and risk of bias using Review Manager 5.3 software. Dissemination: The results of this review will offer implications for the use of Fei-Liu-Ping ointment as an adjunctive treatment for NSCLC. This knowledge will inform recommendations by surgeons and researchers who are interested in the treatment of NSCLC. The results of this systematic review will be disseminated through presentation at a conference and publication of the data in a peer-reviewed journal. Trial registration number: PROSPERO CRD42016036911.
MeSH term(s)	Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/therapy ; Combined Modality Therapy ; Drugs, Chinese Herbal/administration & dosage ; Drugs, Chinese Herbal/therapeutic use ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/therapy ; Nonprescription Drugs/therapeutic use ; Ointments ; Systematic Reviews as Topic ; Treatment Outcome
Chemical Substances	Drugs, Chinese Herbal ; Nonprescription Drugs ; Ointments ; fei-liu-ping
Language	English
Publishing date	2017-01-16
Publishing country	England
Document type	Journal Article
ZDB-ID	2747269-3
ISSN	2044-6055 ; 2044-6055 ; 2053-3624
ISSN (online)	2044-6055
ISSN	2044-6055 ; 2053-3624
DOI	10.1136/bmjopen-2016-015045
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito